AGApril L. Gilbert

April L. Gilbert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


April L. Gilbert has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Table S2 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    Supplementary Table S2. Additional antibodies used for CAR-NK vs CAR-T cell mouse experiments.


  • Open Access

    Figure 3 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    Armoring NK cells with CAR27/IL-15 results in enhanced antitumor activity against multiple myeloma. A, Schematic of the retroviral vector used to transduce CB-NK cells. B, Flow cytometry histogram assay of CD70 surface protein levels in NCI-H929 (blue) and MM.1S (magenta) cells. C,51Cr release assay of NT or CAR27/IL-15 NK cells against CD70+ MM.1S or (D) CD70− NCI-H929 tumor cells at different E:T ratios and measured 4 hours after coincubation (n = 3). E, MM.1S tumor cells transduced to express mKATE were cultured alone or with NT, IL-15, or CAR27/IL-15 NK cells. The number of MM.1S cells was measured over time with sequential images from the Incucyte machine. Representative images from 0 Hours (baseline) and after 24 Hours after coculture are shown. White bar, 400 μm. F, The percentage of initial MM.1S cells from panel (E) is plotted for each group over 30 hours. Bar graph (right) shows the AUC analysis. G, The Incucyte killing assay was repeated for NT and CAR27/IL-15 NK cells against the CD70-positive U266B1 myeloma cell line. Bar graph (right) shows the AUC analysis. Data are represented as mean ± SD. Data for the AUC graphs are represented as mean ± SEM. The P values were determined by two-way ANOVA with Sidak’s multiple comparisons (C), one-way ANOVA with Tukey multiple comparison (F), and unpaired t test (G). ***, P ≤ 0.001. ICD, intracellular domain; LTR, long terminal repeats; TMD, transmembrane domain.

  • Open Access

    Supplementary Fig S1 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    Supplementary Fig. S1. CD70 mRNA expression of patients with multiple myeloma regarding sex and race.

  • Open Access

    Figure 2 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    Phenotypic characterization of CD70 expression in patients with multiple myeloma. A, Bone marrow aspirates from 30 patients with multiple myeloma were stained with anti-CD70 and anti-BCMA antibodies and assayed by flow cytometry. The percentage of positive cells from the FSC/SSC/Single cells/Live-Dead/CD3−/CD19−/CD20−/CD14−/CD138+ population is plotted, with each dot representing one patient sample. The gating strategy is shown in Supplementary Fig. S3. B, The percentage of positive expression (circle size) and the robust z-score calculated from the mean fluorescence intensity (color) for CD70, BCMA, CD38, CS1, CD56, and CD45 proteins from the same population were plotted in a dot plot for each of the patient samples in (A). C, An optimized stochastic neighbor embedding (opt-SNE) plot was generated for each marker in the CD138+, CD3−, CD19/20−, and CD14− populations from an example patient with amp 1q and loss of one copy of TP53. Representative images of IHC CD70 staining of the gingiva (D) and bone marrow (E) clot of a patient with high-grade myeloma. F, CD70 staining of the humerus of a patient who had not responded to the BCMA antibody–drug conjugate belantamab mafodotin. G, CD70 staining from the bone marrow of a patient without multiple myeloma as a control. Scale bar, 100 μm.

  • Open Access

    Figure 1 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    CD70 expression in patients with multiple myeloma. Comparison of CD70 mRNA levels based on (A) RNA levels from the MMRF CoMMpass dataset of different translocations, Amp1q and Del17p, in patients with NDMM and (B) the ISS (n = 561). C, Paired comparison of CD70 mRNA in NDMM and at first relapse (left). The difference between the expression levels is plotted (right, relapsed–NDMM) with a dotted line at the mean of differences (0.609, P = 0.0028, paired t test, n = 61). D, Patients were stratified into tertiles based on CD70 mRNA expression, and overall survival (OS) was plotted (n = 792). Color shading represents the 95% confidence interval. E, Bone marrow aspirates from patients with multiple myeloma (n = 46) from the MD Anderson Cancer Center with different translocations involving chromosome 14 were analyzed for CD70 mRNA using the pseudobulk approach on single cell (sc)-mRNA. The control group included samples from n = 3 healthy control donors. The fourth data point in the control group represents nontumor or polyclonal plasma cells (PC) from patients with multiple myeloma identified by the expression of B-cell receptor VDJ using scRNA-seq (see “Methods”); monoclonal plasma cells were similarly defined based on BCR VDJ sequences, and each remaining data point corresponds to an individual patient with multiple myeloma: no translocation (none; n = 20), t(11;14) (n = 16), t(14;16) (n = 2), and t(4;14) (n = 8). F, The sc-mRNA transcriptome data from all samples projected onto a Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP). Individual CD70 mRNA was mapped at single-cell resolution. G, Translocations involving the immunoglobulin heavy chain locus identified by FISH are mapped onto a UMAP. Box and whisker plots show the median and IQR (25th and 75th percentiles), and the whiskers extend to ±1.5 times the IQR. The P values were determined by the Wilcoxon test [A, B, D (left panel) and E]. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ns, not significant. UMI, unique molecular identifier.

  • Open Access

    Figure 7 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    CAR27/IL-15 NK cells display comparable anti-multiple myeloma activity to CAR27/IL-15 T cells. A, Cytotoxicity of NT NK, CAR27/IL-15 NK, NT T, and CAR27/IL-15 T cells against MM.1S tumor cells was assessed using an Incucyte assay. Bar graph (right) shows AUC analysis. B, NSG mice were injected with MM.1S tumor cells on day −3 and treated on day 0 with CAR27/IL-15 NK cells or CAR27/IL-15 T cells or left untreated (tumor alone). C, Tumor burden was monitored by BLI through day 34. D, BLI signal for individual mice plotted over time. E, Mouse body weight was measured during the study as an indicator of treatment tolerability. Data are represented as mean ± SD. Data for the AUC graph are represented as mean ± SEM. The P values were determined by one-way ANOVA with Tukey multiple comparison (A). ***, P ≤ 0.001.

  • Open Access

    Figure 6 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    CAR27/IL-15 NK cells improve tumor control in a MM.1S TNFRSF17 KO mouse model. A, Mice were first injected with MM.1S TNFRSF17 KO tumor cells on day −3. The mice were subsequently treated (day 0) with no additional cells (tumor alone), NT NK, CAR27/IL-15 NK, CAR27 NK, and IL-15 NK cells. B, BLI was obtained weekly until day 54. Different radiance scales were used for early (days 0–14) and late imaging due to signal intensities spanning several orders of magnitude. An ‘X’ denotes that all mice in the group have died. C, BLI signal for individual mice plotted over days post-CAR NK cell treatment. D, Percentage of human CD45+ cells (NK cells) detected in the blood at day 12 after NK cell infusion. Only three of the five mice per group were bled for this analysis. E, Kaplan–Meier survival plot. Blue asterisks: NT NK vs. CAR27/IL-15 NK; green asterisk: CAR27 NK vs. CAR27/IL-15 NK; and magenta asterisk: IL-15 NK vs. CAR27/IL-15 NK. F, Weight of the mice over time. Data are represented as mean ± SD. P values were calculated using the log-rank test (E). *, P ≤ 0.05; **, P ≤ 0.01.

  • Open Access

    Supplementary Fig S3 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    Supplementary Fig. S3. Flow cytometry gating strategy.

  • Open Access

    Table S1 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    Supplementary Table S1. List of antibodies used for flow cytometry and intracellular cytokine staining.

  • Open Access

    Figure 4 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models

    by Paul Lin, Sunil Acharya, Francia Reyes-Silva, Rafet Basar, Nadima Uprety, Luz Yurany Moreno Rueda, Pei Lin, April L. Gilbert, Pinaki P. Banerjee, Dexing Fang, et al.

    In vivo anti-myeloma activity of CD70-targeting CAR NK cells. A, Mice were first injected with MM.1S tumor cells and subsequently treated (day 0) with no additional cells (tumor alone), NT NK cells, CAR27/IL-15 NK cells, CAR27 NK cells without IL-15 (CAR27), and NK cells transduced to express only IL-15 (IL-15 NK). B, BLI was obtained weekly until day 54. Different radiance scales were used for early (days 0–14) and late (days 21–54) imaging due to signal intensities spanning several orders of magnitude. An ‘X’ denotes that all mice in the group have died. C, BLI signal for individual mice plotted over days post-CAR NK cell treatment. D, Percentage of human CD45+ cells (NK cells) detected in the blood at day 12 after NK cell infusion. Only three of the five mice per group were bled for this analysis. E, Kaplan–Meier survival plot. P value significance is denoted for the following comparisons: blue asterisks: NT NK vs. CAR27/IL-15 NK; green asterisks: CAR27 NK vs. CAR27/IL-15 NK; and magenta asterisks: IL-15 NK vs. CAR27/IL-15 NK. F, Weight of the mice in grams over time. Data are represented as mean ± SD. P values were calculated using the log-rank test (E). **, P ≤ 0.01.